泊马度胺
医学
地塞米松
多发性骨髓瘤
肿瘤科
来那度胺
内科学
耐火材料(行星科学)
重症监护医学
物理
天体生物学
作者
Yu Luo,Chen Li,Yuanchen Niu,Shuqin Wu,Jingyuan Tian,Zhiqin Hu,Jing He,Zhixin Zhang,Haiyan Liu,Yongmei Li,Tenghua Wang,Yi Fang
标识
DOI:10.1080/17474086.2024.2326219
摘要
To evaluate the efficacy and safety of pomalidomide in combination treatment of relapsed/refractory multiple myeloma (RRMM).Published clinical trials were searched in the Cochrane Library, PubMed, EMBASE to February 2023. The literature was screened and evaluated according to the inclusion criteria, and the data were analyzed by a random effect model. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS) and full grade or ≥ 3 adverse events (AEs) were the outcomes.This study included 31 clinical trials, which included 4776 patients. The pooled ORR of the doublet regimens was 33.3% (95%CI: 27-39%) and the triplet regimens was 66% (95%CI: 58-74%). Among the 25 included studies, the median PFS was 8.29 months (95%CI: 7.27-9.31), and nine studies reported median OS of 19.43 months (95%CI: 14.56-24.30). In terms of safety, the most common hematologic AEs of grade ≥ 3 were neutropenia (41%) and anemia (20%); Non-hematologic AEs were pneumonia (14%) and infection/febrile neutropenia (14%).Pomalidomide combined treatment regimens have shown good clinical efficacy, especially in pomalidomide + dexamethasone combined with other drugs. In terms of safety, it's important to pay attention to the likelihood of hematological adverse events when used clinically.
科研通智能强力驱动
Strongly Powered by AbleSci AI